ISTH 2024 Supported Symposia & Presentation Theaters
 

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2024 Congress in Bangkok, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis. 

​

See below for session titles, dates and times.

​

Saturday, June 22, 11:30 - 12:45 Supported Symposia

• Complement Dysregulation in Atypical Hemolytic Uremic Syndrome (aHUS): Approaches to Diagnosis and Management (Alexion, AstraZeneca Rare Disease)
  Room 110

• iTTP Time Capsule: Celebrating a Century of Breakthroughs and Envisioning Tomorrow (Sanofi)
  Room 111

• Precision Therapeutics With CRISPR-Based Targeted Gene Insertion Technology: Imagining the Future of Hemophilia (Regeneron)
  Room 209

​

Sunday, June 23, 12:15 - 13:30 Supported Symposia

• Building Momentum to Raise the Standard of Care in Bleeding Disorders (CSL Behring)
  Room 110​

• Elevating Hemophilia A Care to Unprecedented Levels: Enhancing Protection With Innovative Therapies (Sanofi / Sobi)
  Room 111

• Learn About Tomorrow’s Advances Today – Breakthroughs in All-Round Bleed Protection (Octapharma)
  Room 208

• From guidelines to practice: tailored interventions for rare hemostatic situations (Takeda)
  Room 209

• Advancing Care with Concizumab: A Novel Class of Anti-TFPI Monoclonal Antibody for Haemophilia With Inhibitors (Novo Nordisk Healthcare AG)
  Room 210

• Your Frequently Asked Questions: Our Responses on VTE Anticoagulation (Bristol Myers Squibb/Pfizer) 
  Room 211

​

Sunday, June 23, 13:45 - 14:30 Presentation Theaters

• HEMLIBRA (Emicizumab) Clinical Management – Supporting People With Haemophilia A Throughout Their Lives (F. Hoffman-La Roche Ltd)
  Presentation Theater #1

• Should prophylaxis be the standard of care for patients with VWD? (Takeda)
  Presentation Theater #2

• Solutions to Maximize Your Lab Productivity (Stago)
  Presentation Theater #3​

​​

Monday, June 24, 12:15 - 13:30 Supported Symposia

• Taking a Closer Look: The Impact of Liver Health on Gene Therapy for Hemophilia A (Spark Therapeutics)
  Room 110

• Re-imagining Thrombotic Thrombocytopenic Purpura (TTP) Management Goals 100 Years From its Discovery (Takeda)
  Room 111

• Clinical Perspectives on the Management of Severe Bleeding in Patients Treated with Factor-Xa Inhibitors (AstraZeneca)
  Room 208

• Innovations in Hemophilia Management: Navigating Changes in Clinical Practice with Rebalancing Agents (Sanofi)​
  Room 209

• Next-Level Insights on Prophylaxis in von Willebrand Disease – Are You Addressing Your Patients’ Needs? (Octapharma)
  Room 210

• Advancing Hemophilia Care: Moving From Innovation to Implementation (Pfizer)
  Room 211

​​

Monday, June 24, 13:45 - 14:30 Presentation Theaters

• What Can High-Sustained Factor VIII Levels Mean for Hemophilia A Patients? A Practical Discussion (Sanofi)
  Presentation Theater #1

• Providing Innovation in Care: Daily Protection With Alhemo® for Haemophilia With Inhibitors (Novo Nordisk Healthcare AG)
  Presentation Theater #2

• Learning Through Shared Experience: Gene Therapy for Haemophilia B (CSL Behring)
  Presentation Theater #3

​​

Tuesday, June 25, 12:15 - 13:30 Supported Symposia

• Mim8: A Novel FVIIIa Mimetic for Haemophilia A Patients With and Without Inhibitors (Novo Nordisk Healthcare AG)
  Room 110

• The ITP Treatment Landscape: a Focus on Patient Perspectives and Unmet Clinical Needs (Sanofi)
  Room 111

​​

Tuesday, June 25, 13:45 - 14:30 Presentation Theaters

• Advancing the Standard of Care in Haemophilia A Prophylaxis: The Impact of HEMLIBRA (Emicizumab) (F. Hoffman-La Roche Ltd)
  Presentation Theater #1

• ROCTAVIAN™ (valoctocogene roxaparvovec): From decision-making to dosing and beyond (BioMarin Pharmaceutical Inc)
  Presentation Theater #2

• The Evolution of Hemophilia Treatments and Lab Testing (Werfen)
  Presentation Theater #3